CAD Therapeutics, Inc.
About CAD Therapeutics, Inc.
CAD Therapeutics is a privately held, U.S.-based clinical-stage biotechnology company developing a novel investigational approach and drug formulation for PTSD. The company focuses on a physiological reset of the nervous system's overactive stress response rather than symptom management with daily psychiatric medication. Its lead asset is the drug Clonicaine™ used in combination with the Stellate Ganglion Block procedure, both covered under issued U.S. patents.
- 🔗 CAD Therapeutics — A Physiological Approach to PTSD
- 🔗 Biotech Firm Secures $32M CAD Financing Led by Investissement Québec | Kainova Therapeutics posted on the topic | LinkedIn
- 🔗 SCRA Announces New Member Companies and Grant Funding - SCRA: South Carolina Research Authority
- 🔗 The 50 best-funded biotech companies of 2026
- 🔗 Biotech Impact - Stem Cell Network
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- CAD Therapeutics is developing Clonicaine™ combined with Stellate Ganglion Block for PTSD.
- The approach aims to reset overactive stress responses rather than manage symptoms daily.
- Company holds issued U.S. patents covering both the drug and its procedural use.
- Raised $4M in private placement with no investors disclosed.
- Privately held clinical-stage biotech focused on physiological PTSD treatment.
Ask StreetZero about CAD Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account